| Hearing loss (diagnosed clinically and through audiometry) aOR (95% CI) | Hearing loss confirmed by audiometry aOR (95% CI) | Hearing loss diagnosed clinically aOR (95% CI) | |
---|---|---|---|---|
Age category in years | 15 – 29 years | 1.00 | 1.00 | 1.00 |
30 – 39 years | 3.8 (1.46 – 9.88) | 2.88 (0.96 – 8.63) | 4.89 (1.26 – 18.97) | |
40 – 49 years | 5.21 (1.93 – 14.04) | 4.49 (1.44 – 14.00) | 5.57 (1.39 – 22.36) | |
≥ 50 years | 2.78 (0.83 – 9.34) | 1.99 (0.46 – 7.87) | 4.12 (0.83 – 20.51) | |
Sex | Female | 1.00 | 1.00 | 1.00 |
Male | 0.72 (0.46 – 1.37) | 0.78 (0.467 – 1.30) | 0.64 (0.37 – 1.11) | |
HIV status | HIV infection | 1.32 (0.83 – 2.12) | 1.53 (0.89 – 2.62) | 1.13 (0.62 – 2.06) |
TB treatment history | Never treated for TB before | 1.00 | 1.00 | 1.00 |
New TB regimen | 1.24 (0.51 – 3.04) | 1.01 (0.38 – 3.02) | 1.47 (0.46 – 4.66) | |
Retreatment regimen | 1.64 (0.69 – 3.91) | 1.63 (0.60 – 4.36) | 1.56 (0.51 – 4.78) | |
*Treated for MDR–TB | Predicts outcome perfectly | Predicts outcome perfectly | Predicts outcome perfectly | |
Mean creatinine clearance per month in millilitre [mL]/minute | > 60Â mL/minute | 1.00 | 1.00 | 1.00 |
40 – 60 mL/minute | 1.48 (1.05 – 2.09) | 1.07 (0.50 – 2.28) | 1.27 (0.54 – 2.98) | |
20 – 40 mL/minute | 1.81 (0.87 – 3.75) | 3.35 (1.07 – 10.53) | 1.19 (0.29 – 4.82) | |
< 20 mL/minute | 1.51 (0.67 – 3.36) | 1.52 (0.34 – 6.71) | 1.18 (0.25 – 5.40) | |
£Duration of amikacin treatment in months | 1.98 (1.86 – 2.12) | 1.85 (0.94 – 3.99) | 1.93 (0.89 – 3.97) | |
¥Mean dose of amikacin per kilogram per month | 1.15 (1.04 – 1.28) | 1.11 (1.00 – 1.23) | 1.18 (1.04 – 1.33) | |
Interaction between the duration of amikacin treatment and amikacin dose | 1.23 (1.11 – 1.35) |  |  |